Engineered proteins for drug delivery
Wouter Verdurmen’s research group focuses on designing and investigating engineered proteins that overcome delivery barriers, employing synthetic binding proteins for target recognition. Various (super-resolution) microscopy techniques as well as microfluidic tumor-on-a-chip approaches are used.read more
Engineered proteins for drug deliveryWouter Verdurmen’s research group focuses on designing and investigating engineered proteins that overcome delivery barriers, employing synthetic binding proteins for target recognition. Various (super-resolution) microscopy techniques as well as microfluidic tumor-on-a-chip approaches are used.
Fig 1) Infection of EGFR receptor-retargeted adenoviruses (green) in a co-culture spheroid of tumor cells (cyan) and fibroblasts (red).
Fig 2) Delivery of DARPins (red) targeting the cancer-associated Her2 receptor into a spherical tumor mass of BT474 cells (cyan).
Aims of this research group
This group follows three aims that center around engineered proteins in drug delivery: understanding and improving how therapeutic proteins reach the cytosol, establishing methods to investigate tumor-targeted drug delivery in 3D and improving tumor delivery of protein drugs in complex tissues.read more
Aims of this research groupThe research performed within my group follows three aims that center around the use of engineered proteins in drug delivery.
Understanding and improving how therapeutic proteins reach the cytosolCurrently, only a minority of intracellular targets can be therapeutically addressed. Most potential intracellular targets have thus remained undruggable. One possible approach is the cytosolic delivery of therapeutic proteins. We aim to understand cytosolic protein translocation and develop effective strategies for cytosolic delivery of therapeutic proteins, utilizing protein domains found in nature to enable membrane translocation.
Establishing methods to investigate tumor-targeted drug delivery in 3DTo investigate how therapeutic proteins reach cells within a tumor, we use microfluidic tumor-on-a-chip devices. These models enable a controlled study of factors involved in drug delivery and will ultimately lead to a better quantitative understanding of the transport processes that occur in and around tumor tissues.
Improving tumor delivery of protein drugs in complex tissuesFollowing the second aim, my group aims to implement strategies to improve tissue penetration of novel therapeutic agents, focusing either on tuning of drug properties or locally altering the tumor microenvironment.
Related research groups
Research group Genetic therapy for inherited retinal disease
Rob Collin's research group aimes at the development of new preclinical therapeutic strategies for selected genetic subtypes of inherited retinal dystrophy, by applying different approaches and using various cellular and animal models.read more
Radboudumc Technology Center Animal research facility
This technology center offers advice and support from planning up to and including the conduct of animal research on behalf of biomedical research and education.read more